Laura M. Bruzek
- Molecular Biology top 10%
- Oncology top 5%
- Hematology top 5%
- Pulmonary and Respiratory Medicine
- Pathology and Forensic Medicine top 10%
- Co-authors
- Alex A. AdjeiScott H. KaufmannLorelei J. HansonCharles ErlichmanChristopher A. CarterGregory J. GoresChunrong YuXue Meng
- Topics
- Cancer Treatment and Pharmacology (8 papers)Cancer-related Molecular Pathways (6 papers)Advanced Breast Cancer Therapies (3 papers)
- Cited by
- HematologyOncologyMolecular Biology
- Partner nations
- United StatesUkraineIsrael
In The Last Decade
Laura M. Bruzek
15 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 69
- Molecular Biology 827
- Oncology 530
- Hematology 236
- Pulmonary and Respiratory Medicine 172
- Pathology and Forensic Medicine 163
Countries citing papers authored by Laura M. Bruzek
This map shows the geographic impact of Laura M. Bruzek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura M. Bruzek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura M. Bruzek more than expected).
Fields of papers citing papers by Laura M. Bruzek
This network shows the impact of papers produced by Laura M. Bruzek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura M. Bruzek. The network helps show where Laura M. Bruzek may publish in the future.
Co-authorship network of co-authors of Laura M. Bruzek
This figure shows the co-authorship network connecting the top 25 collaborators of Laura M. Bruzek. A scholar is included among the top collaborators of Laura M. Bruzek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura M. Bruzek. Laura M. Bruzek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 35 | |
| 2 | 129 | |
| 3 | 228 | |
| 4 | 10 | |
| 5 | The Raf kinase Inhibitor BAY 43-9006 accelerates Mcl-1 degradation and regulates pro-apoptotic function | 4 |
| 6 | 58 | |
| 7 | 316 | |
| 8 | 23 | |
| 9 | 1 | |
| 10 | 1 | |
| 11 | A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. | 40 |
| 12 | 58 | |
| 13 | 168 | |
| 14 | Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. | 87 |
| 15 | 4 |
About Laura M. Bruzek
Laura M. Bruzek is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine, having authored 15 papers that have together received 1.2k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (8 papers), Cancer-related Molecular Pathways (6 papers) and Advanced Breast Cancer Therapies (3 papers). The work is most often cited by research in Hematology (236 citations), Oncology (530 citations) and Molecular Biology (827 citations). Laura M. Bruzek has collaborated with scholars based in United States, Ukraine and Israel. Frequent co-authors include Alex A. Adjei, Scott H. Kaufmann, Lorelei J. Hanson, Charles Erlichman, Christopher A. Carter, Gregory J. Gores, Chunrong Yu, Xue Meng, Joel M. Reid and James R. Wright. Their work appears in journals such as Journal of Clinical Oncology, Blood and Oncogene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.